Humacyte, a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company's proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/20/15 | $150,000,000 | Series B |
Access Industries Bangkok Bank Public Company Brady Dougan Gavril Yushvaev Pacific Eagle Asset Management Reignwood Group | undisclosed |
